Adicet bio reports first quarter 2025 financial results and provides business updates

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended march 31, 2025. “we are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon,” said chen schor, president and chief executive officer.
ACET Ratings Summary
ACET Quant Ranking